Article
Cardiac & Cardiovascular Systems
Derek S. Chew, Yanhong Li, Robert Bigelow, Patricia A. Cowper, Kevin J. Anstrom, Melanie R. Daniels, Linda Davidson-Ray, Adrian F. Hernandez, Christopher M. O'Connor, Paul W. Armstrong, Daniel B. Mark
Summary: The VICTORIA trial showed that Vericiguat reduced the risk of cardiovascular death or heart failure hospitalization in high-risk heart failure patients. However, the treatment effect varied depending on baseline NT-proBNP levels. The economic analysis revealed that the cost-effectiveness of Vericiguat was influenced by the observed NT-proBNP treatment effect heterogeneity.
Article
Cardiac & Cardiovascular Systems
Michele Senni, Jose Lopez-Sendon, Alain Cohen-Solal, Piotr Ponikowski, Richard Nkulikiyinka, Cecilia Freitas, Vanja Miodrag Vlajnic, Lothar Roessig, Burkert Pieske
Summary: The treatment response to vericiguat in heart failure patients is influenced by baseline NT-proBNP levels, with patients with higher NT-proBNP values potentially not benefiting from the treatment.
Article
Cardiac & Cardiovascular Systems
Piotr Ponikowski, Wendimagegn Alemayehu, Ali Oto, M. Cecilia Bahit, Ebrahim Noori, Mahesh J. Patel, Javed Butler, Justin A. Ezekowitz, Adrian F. Hernandez, Carolyn S. P. Lam, Christopher M. O'Connor, Burkert Pieske, Lothar Roessig, Adriaan A. Voors, Cynthia Westerhout, Paul W. Armstrong
Summary: This study evaluated the relationship between baseline and new-onset atrial fibrillation (AF) and outcomes in patients with worsening heart failure (HF) with reduced ejection fraction in VICTORIA. A history of AF alone at baseline was associated with an increased risk of cardiovascular death, while neither type of AF affected the beneficial effect of vericiguat. Development of AF post-randomization was associated with an increase in cardiovascular death and HF hospitalization risk, unaffected by vericiguat treatment.
EUROPEAN JOURNAL OF HEART FAILURE
(2021)
Article
Cardiac & Cardiovascular Systems
Justin A. Ezekowitz, Yinggan Zheng, Alain Cohen-Solal, Vojtech Melenovsky, Jorge Escobedo, Javed Butler, Adrian F. Hernandez, Carolyn S. P. Lam, Christopher M. O'Connor, Burkert Pieske, Piotr Ponikowski, Adriaan A. Voors, Christopher deFilippi, Cynthia M. Westerhout, Ciaran McMullan, Lothar Roessig, Paul W. Armstrong
Summary: In the VICTORIA trial, anemia was more common in patients treated with vericiguat compared to placebo. While lower hemoglobin levels were associated with more clinical events, the treatment benefit of vericiguat was not affected by changes in hemoglobin levels over time.
Article
Cardiac & Cardiovascular Systems
Javed Butler, Amanda Stebbins, Vojtech Melenovsky, Nancy K. Sweitzer, Martin R. Cowie, Josef Stehlik, Muhammad Shahzeb Khan, Robert O. Blaustein, Justin A. Ezekowitz, Adrian F. Hernandez, Carolyn S. P. Lam, Richard Nkulikiyinka, Christopher M. O'Connor, Burkert M. Pieske, Piotr Ponikowski, John A. Spertus, Adriaan A. Voors, Kevin J. Anstrom, Paul W. Armstrong
Summary: This study investigated the effects of vericiguat compared with placebo on health status outcomes in heart failure patients. The Kansas City Cardiomyopathy Questionnaire was used to measure the outcomes. The results showed that vericiguat did not significantly improve the KCCQ scores compared with placebo. However, vericiguat reduced the risk of cardiovascular death or heart failure hospitalization across the range of baseline health status.
CIRCULATION-HEART FAILURE
(2022)
Article
Biochemistry & Molecular Biology
Timea Magdolna Szabo, Elod Erno Nagy, Adam Kirchmaier, Erhard Heidenhoffer, Hunor-Laszlo Gabor-Kelemen, Marius Frasineanu, Judit Cseke, Marta German-Sallo, Attila Frigy, Jun Sun
Summary: Vitamin D plays an important role as a prognostic biomarker in heart failure, although its therapeutic implications are still debated. This study found a close correlation between 25(OH)D and LVEF, as well as a significant positive correlation between 25(OH)D, serum uric acid, and albumin levels in HF patients. Furthermore, 25(OH)D concentration independently affected LVEF, supporting the need for establishing proper vitamin D supplementation schemes and dietary interventions in HF.
Article
Cardiac & Cardiovascular Systems
Safia Chatur, Muthiah Vaduganathan, Brian Claggett, Orly Vardeny, Akshay S. Desai, Pardeep S. Jhund, Rudolf A. de Boer, Carolyn S. P. Lam, Mikhail N. Kosiborod, Sanjiv J. Shah, Felipe Martinez, Silvio E. Inzucchi, Adrian F. Hernandez, Tariq Haddad, Sumeet S. Mitter, Zi Michael Miao, Magnus Petersson, Anna Maria Langkilde, John J. McMurray, Scott D. Solomon
Summary: In this study, the safety and efficacy of dapagliflozin were evaluated according to different diuretic therapies and its influence on diuretic use. The results showed that dapagliflozin had consistent clinical benefits in terms of reducing heart failure worsening and cardiovascular death across different diuretic categories and doses, with a similar safety profile. Dapagliflozin also significantly reduced the need for loop diuretics over time.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Stephen J. Greene, Justin A. Ezekowitz, Kevin J. Anstrom, Vladimir Demyanenko, Michael M. Givertz, Ileana L. Pina, Christopher M. O'connor, Joerg Koglin, Lothar Roessig, Adrian F. Hernandez, Paul W. Armstrong, Robert J. Mentz
Summary: This study investigated the medication changes during hospitalizations for heart failure with reduced ejection fraction (HFrEF) in North American clinical practice. The majority of eligible patients remained on stable subtarget doses or without medication at admission and discharge, with favorable medication changes associated with hospitalization in Canada and specific patient characteristics.
JOURNAL OF CARDIAC FAILURE
(2022)
Article
Cardiac & Cardiovascular Systems
Carlos G. Santos-Gallego, Ariana P. Vargas-Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, Donna Mancini, Sean Pinney, Frank Macaluso, Samantha Sartori, Merce Roque, Fernando Sabatel-Perez, Anderly Rodriguez-Cordero, M. Urooj Zafar, Icilma Fergus, Farah Atallah-Lajam, Johanna P. Contreras, Cathleen Varley, Pedro R. Moreno, Vivian M. Abascal, Anuradha Lala, Ronald Tamler, Javier Sanz, Valentin Fuster, Juan J. Badimon
Summary: This study found that empagliflozin significantly improved left ventricular function and volumes, functional capacity, and quality of life in nondiabetic HFrEF patients, compared to placebo. The observations strongly support the role of sodium-glucose cotransporter 2 inhibitors in the treatment of HFrEF patients regardless of their glycemic status.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Joao Pedro Ferreira, Stuart J. Pocock, Peter Carson, Inder Anand, Wolfram Doehner, Markus Haass, Michel Komajda, Alan Miller, Steen Pehrson, John R. Teerlink, Martina Brueckmann, Waheed Jamal, Cordula Zeller, Sven Schnaidt, Faiez Zannad
Summary: Empagliflozin reduces the risk and total number of worsening heart failure events in patients with heart failure and reduced ejection fraction, with benefits seen early after treatment initiation and sustained throughout the therapy.
Article
Cardiac & Cardiovascular Systems
Robert J. H. Miller, Majid Nabipoor, Erik Youngson, Gynter Kotrri, Nowell M. Fine, Jonathan G. Howlett, Ian D. Paterson, Justin Ezekowitz, Finlay A. McAlister
Summary: Among patients with HFmrEF, those with positive LVEF trajectory are less likely to experience adverse outcomes after adjusting for important confounders, including medical therapy. Categorizing HFmrEF patients based on LVEF trajectory provides meaningful clinical information and may assist clinicians with management decisions.
Article
Cardiac & Cardiovascular Systems
Yogesh N. Reddy, Barry A. Borlaug, Bernard J. Gersh
Summary: Atrial fibrillation is the most common arrhythmia in heart failure patients and can be both the cause and consequence of clinical heart failure. Some patients may benefit from maintaining sinus rhythm with catheter ablation. There is a close relationship between atrial fibrillation, left atrial myopathy, mitral regurgitation, and heart failure with preserved ejection fraction, with potential clinical benefits to catheter ablation therapy. Treatment of atrial fibrillation also requires consideration of the degree of atrial myopathy and chronicity of atrial fibrillation.
Article
Cardiac & Cardiovascular Systems
Li Shen, Pardeep Singh Jhund, Kieran Francis Docherty, Muthiah Vaduganathan, Mark Colquhoun Petrie, Akshay Suvas Desai, Lars Kober, Morten Schou, Milton Packer, Scott David Solomon, Xingwei Zhang, John Joseph Valentine McMurray
Summary: Previous guidelines for treating heart failure with reduced ejection fraction recommended initiating therapy in a chronological order based on trial history. However, this study suggests that accelerating treatment titration and optimizing treatment ordering may improve patient outcomes.
EUROPEAN HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Robert J. Mentz, Hillary Mulder, Arend Mosterd, Nancy K. Sweitzer, Michele Senni, Javed Butler, Justin A. Ezekowitz, Carolyn S. P. Lam, Burkert Pieske, Piotr Ponikowski, Adriaan A. Voors, Kevin J. Anstrom, Paul W. Armstrong, Christopher M. O'connor, Adrian F. Hernandez
Summary: The study focused on predicting outcomes in high-risk HF patients with recent worsening events. Data from 2524 participants were analyzed to identify independent predictors of increased risk for HF hospitalization or cardiovascular death, including HF characteristics, medical history, and laboratory values. The predictive models developed in the study performed well in identifying high-risk patients receiving guideline-based care.
JOURNAL OF CARDIAC FAILURE
(2021)
Article
Cardiac & Cardiovascular Systems
Patrick M. Pilz, Jennifer E. Ward, Wei-Ting Chang, Attila Kiss, Edward Bateh, Alokkumar Jha, Sudeshna Fisch, Bruno K. Podesser, Ronglih Liao
Summary: This article outlines the strengths, limitations, and outcomes of small and large animal models of heart failure with reduced ejection fraction currently used in basic and translational research. Animal models play a critical role in understanding the molecular mechanisms of heart failure, although no model completely recapitulates the full human disease.
CIRCULATION RESEARCH
(2022)